Trial Profile
A prospective Single-center Study of Pharmacokinetics and Pharmacogenetics of Regorafenib in Patients with Metastatic Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2022
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Pharmacogenomic
- 27 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 26 May 2020 Status changed from active, no longer recruiting to recruiting.
- 17 Sep 2018 Status changed from not yet recruiting to active, no longer recruiting.